{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:31:27Z","timestamp":1778884287005,"version":"3.51.4"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Korea government","award":["2021R1A2C1013797"],"award-info":[{"award-number":["2021R1A2C1013797"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We prospectively investigated the potential of tumor-informed circulating tumor DNA (ctDNA) for detecting minimal residual disease (MRD) in surgically resected biliary tract cancer (BTC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Personalized panels were developed using individual variants identified from the whole-exome sequencing of surgical specimens from each patient. Two sequential blood samples, collected preoperatively and within 6 weeks after surgery, were analyzed. A positive ctDNA result was defined as the identification of two or more patient-specific mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 18 patients were enrolled. However, 1 patient was excluded due to inoperability detected during surgery, and personalized target panels could not be created for 3 patients due to a low number of target variants, resulting in the analysis of 14 patients. There was a tendency for a higher preoperative ctDNA positivity rate in an advanced overall stage (100% in stage III-IV vs. 44.4% in stage I-II, p\u2009=\u20090.126) and node-positive disease (100% in node-positive vs. 60% in node-negative, p\u2009=\u20090.210). After a median follow-up of 17.4 months (range, 11.4\u201331.1), the 1-year and 2-year progression-free survival (PFS) rates were 78.6% and 58.2%, respectively. Changes in ctDNA positivity status were negative to negative in 3 patients (25.0%), positive to negative in 3 patients (25.0%), and positive to positive in 6 patients (50%). Additionally, there was a trend for an association between poorer PFS and both preoperative and postoperative ctDNA positivity. Among ctDNA-negative patients before surgery, no progression was observed; however, 5 out of 10 ctDNA-positive patients experienced progression. Postoperatively, only 1 out of 6 ctDNA-negative patients experienced progression, in contrast to 3 out of 6 patients with a positive ctDNA result.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although limited by the small sample size, our results may indicate a possible role for tumor-informed ctDNA analysis in detecting MRD in surgically resected BTC and warrant further validation in larger studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0341432","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:31:20Z","timestamp":1769020280000},"page":"e0341432","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Feasibility of tumor-informed circulating tumor DNA for detecting minimal residual disease in surgically resected biliary tract cancer"],"prefix":"10.1371","volume":"21","author":[{"given":"Younghee","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunji","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwang-Phil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Soo","family":"Kyung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngeun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seog Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Mi","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6093-1294","authenticated-orcid":true,"given":"Kyubo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"9","key":"pone.0341432.ref001","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"JM Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"pone.0341432.ref002","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin","volume":"73","author":"D Moris","year":"2023"},{"issue":"18","key":"pone.0341432.ref003","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study","volume":"40","author":"J Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"pone.0341432.ref004","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer","volume":"5","author":"T Reinert","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"pone.0341432.ref005","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41419-020-2531-z","article-title":"Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer","volume":"11","author":"J Yang","year":"2020","journal-title":"Cell Death Dis"},{"issue":"24","key":"pone.0341432.ref006","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer","volume":"386","author":"J Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"pone.0341432.ref007","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2024.42.3_suppl.6","article-title":"Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: Updated analysis from GALAXY study in the CIRCULATE-JAPAN.","volume":"42","author":"H Yukami","year":"2024","journal-title":"JCO"},{"key":"pone.0341432.ref008","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1407","article-title":"114P Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers","volume":"34","author":"G King","year":"2023","journal-title":"Annals of Oncology"},{"issue":"1","key":"pone.0341432.ref009","doi-asserted-by":"crossref","first-page":"485","DOI":"10.21037\/jgo-23-815","article-title":"Circulating tumor DNA analysis guiding adjuvant treatment in resected stage III cholangiocarcinoma: a case report","volume":"15","author":"J Yu","year":"2024","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"pone.0341432.ref010","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4143\/crt.2023.780","article-title":"Barriers in Oligometastasis Care in Korea: Radiation Oncologists\u2019 Perspectives","volume":"55","author":"EK Chie","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"2","key":"pone.0341432.ref011","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41416-023-02300-3","article-title":"Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer","volume":"129","author":"S-B Ryoo","year":"2023","journal-title":"Br J Cancer"},{"issue":"17","key":"pone.0341432.ref012","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/bty560","article-title":"fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"S Chen","year":"2018","journal-title":"Bioinformatics"},{"issue":"14","key":"pone.0341432.ref013","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"H Li","year":"2009","journal-title":"Bioinformatics"},{"key":"pone.0341432.ref014","author":"D Benjamin","year":"2019","journal-title":"Calling Somatic SNVs and Indels with Mutect2"},{"issue":"2","key":"pone.0341432.ref015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","article-title":"Accelerating Discovery of Functional Mutant Alleles in Cancer","volume":"8","author":"MT Chang","year":"2018","journal-title":"Cancer Discov"},{"key":"pone.0341432.ref016","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"MJ Landrum","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"pone.0341432.ref017","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","author":"ST Sherry","year":"2001","journal-title":"Nucleic Acids Res"},{"issue":"7809","key":"pone.0341432.ref018","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"KJ Karczewski","year":"2020","journal-title":"Nature"},{"issue":"22","key":"pone.0341432.ref019","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz7835","article-title":"Korean Genome Project: 1094 Korean personal genomes with clinical information","volume":"6","author":"S Jeon","year":"2020","journal-title":"Sci Adv"},{"issue":"7","key":"pone.0341432.ref020","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","article-title":"Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring","volume":"26","author":"A Zviran","year":"2020","journal-title":"Nat Med"},{"issue":"11","key":"pone.0341432.ref021","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1158\/1078-0432.CCR-19-3005","article-title":"Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer","volume":"26","author":"HA Parsons","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"pone.0341432.ref022","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles","volume":"18","author":"F Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"pone.0341432.ref023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2021.07.045","article-title":"Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14)","volume":"157","author":"K Kim","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"pone.0341432.ref024","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2024.10.043","article-title":"Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma","volume":"82","author":"C Yoo","year":"2025","journal-title":"J Hepatol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:31:28Z","timestamp":1769020288000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341432"}},"subtitle":[],"editor":[{"given":"Daryono Hadi","family":"Tjahjono","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0341432","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}